0Y3M.LSE Prothena Corp. PLC

Healthcare Commercial Services & Supplies London Exchange
- USD
Market cap
-
P/E
6.2x
P/B
-
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2023.

Is 0Y3M.LSE undervalued?

Graham number

The Graham number of Prothena Corp. PLC cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Prothena Corp. PLC fundamental analysis

No fundamental analysis for Prothena Corp. PLC yet.

Prothena Corp. PLC stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Prothena Corp. PLC

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation. Its product pipeline includes Prasinezumab, an investigational humanized monoclonal antibody which is in Phase 3 clinical trial for the treatment of parkinson's disease and other synucleinopathies. The company also develops Coramitug, an investigational antibody, which is in Phase 3 clinical trial fo…

Full company profile